Abarelix

Drug Profile

Abarelix

Alternative Names: Abarelix-depot-F; Abarelix-depot-M; Abarelix-L; Beta-abarelix; Plenaxis; PPI 149; R 3827; β-abarelix

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indiana University
  • Developer Contura
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action LHRH receptor antagonists; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Discontinued Endometriosis

Most Recent Events

  • 19 Jan 2018 Speciality European Pharma rebrands itself as Contura
  • 21 Sep 2017 Launched for Prostate cancer in Luxembourg and Belgium (IM) before September 2017 (Speciality European Pharma website, September 2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top